Displaying 1 - 12 of 46
Metabolism, Alcohol & Toxicity

Summary and Closing remarks

Webcasts
View
Metabolism, Alcohol & Toxicity

Pathophysiological analysis of MASH: targetting clinical manifestations

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Approaching MASH as a metabolic disease with the need for holistic therapy

Webcasts
View
Metabolism, Alcohol & Toxicity

Panel Discussion

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

CymaBay Therapeutics: "Resetting the ideal goals of PBC treatment: A case – based discussion"  (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Introduction

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Case Based Discussion on Biochemical Normalization

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Case Based Discussion on QOL/Pruritus

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Conclusion

Webcasts
View
Displaying 1 - 12 of 46